Bioactive Compounds from Invertebrates: A Promising Source of Novel Drug Development

Rajendra Prasad MR[1], Shantiya K[2], Manjunatha M[3], Mohammed Younus Javeed[4], Zeeshan Afsar*[5]

[1]Department of Pharmacognosy, Farooqia College of Pharmacy, Mysuru, Karnataka
[2] Department of Pharmacy Practice, Devaki Amma memorial College of Pharmacy, Malappuram, Kerala
[3] Department of Pharmaceutics, Manonidhi College of Pharmacy, Chamarajanagar, Karnataka
[4] Department of Pharmacology, Paratab Narender Reddy College of Pharmacy, Hyderabad, Telangana
[5*] Department of Pharmacognosy, College of Pharmacy, Kannur Medical College, Kannur, Kerala

Abstract

Invertebrates constitute nearly 95% of all known animal species and represent an abundant yet underexplored source of bioactive compounds with remarkable therapeutic potential. Owing to their unique biochemical diversity, numerous invertebrates have contributed significantly to modern medicine through the discovery of novel drugs, biomaterials, and diagnostic tools. This review provides a comprehensive overview of the role of medicinal invertebrates in the treatment and management of various medical conditions, highlighting their bioactive constituents, mechanisms of action, therapeutic applications, commercially available products, and future prospects. The review discusses medically important invertebrates, including medicinal leeches, maggots, honeybees, earthworms, horseshoe crabs, marine sponges, cone snails, and silkworms. Advances in genomics, proteomics, metabolomics, marine biotechnology, recombinant protein technology, and biomaterials research are accelerating the discovery and sustainable development of invertebrate-derived therapeutics. Despite challenges related to biodiversity conservation, large-scale production, and regulatory approval, invertebrates continue to offer immense opportunities for pharmaceutical innovation.

Keywords: Invertebrates, Bioactive compounds, Drug discovery, Natural products, Marine biotechnology, Therapeutics, Pharmaceutical sciences.

Introduction

Invertebrates, animals that lack a vertebral column, represent nearly 95% of all known animal species and inhabit a wide range of terrestrial and aquatic ecosystems. These organisms have evolved diverse physiological and biochemical mechanisms for survival, resulting in the production of numerous bioactive compounds with significant medicinal value. Over the past few decades, invertebrates have gained considerable attention as a rich source of novel therapeutic agents for the prevention, diagnosis, and treatment of various medical conditions.

Historically, several invertebrates have been used in traditional medicine. For example, medicinal leeches have been employed for bloodletting and are now widely used in reconstructive and microsurgery to improve venous circulation. Sterile maggots are used in wound debridement therapy to remove dead tissue and promote wound healing, while honey produced by bees has long been recognized for its antimicrobial, anti-inflammatory, and wound-healing properties. Advances in biotechnology and pharmacology have further revealed the therapeutic potential of marine invertebrates such as sponges, cone snails, corals, and tunicates, which produce structurally unique compounds with anticancer, antiviral, antibacterial, analgesic, and anti-inflammatory activities.

Several clinically important drugs have originated from invertebrates. For instance, the cone snail peptide ziconotide is an effective analgesic for severe chronic pain, while compounds isolated from marine sponges have contributed to the development of anticancer and antiviral medications. In addition, horseshoe crab blood plays a crucial role in pharmaceutical quality control through the Limulus Amebocyte Lysate (LAL) test, which is used worldwide to detect bacterial endotoxins in vaccines, injectable drugs, and medical devices.

The increasing prevalence of antimicrobial resistance, chronic diseases, and emerging infections has intensified the search for new therapeutic agents from natural sources. Invertebrates offer an enormous and largely untapped reservoir of biologically active molecules with diverse chemical structures and pharmacological properties. Modern techniques in genomics, proteomics, metabolomics, and biotechnology have accelerated the discovery and development of invertebrate-derived compounds, opening new opportunities for innovative drug development.

This review aims to provide a comprehensive overview of the role of invertebrates in the treatment and management of medical conditions. It discusses the major medicinal invertebrates, their bioactive compounds, mechanisms of action, therapeutic applications, commercially available drugs, current research, challenges, and future prospects in the field of pharmaceutical and biomedical sciences.

Medicinal Leeches

Medicinal leeches (*Hirudo medicinalis*) have been used in healthcare for centuries and remain valuable in modern medicine, particularly in reconstructive and microsurgery. They are commonly employed after plastic surgery, skin grafting, and tissue reattachment procedures to relieve venous congestion and restore blood circulation. The therapeutic effects of leeches are mainly due to the complex mixture of bioactive compounds present in their saliva. These include hirudin, a potent anticoagulant that prevents blood clot formation by inhibiting thrombin; calin, which inhibits platelet aggregation; destabilase, a fibrinolytic enzyme capable of dissolving blood clots; hyaluronidase, which increases tissue permeability and facilitates the diffusion of other active molecules; and proteins such as bdellins and eglins, which possess anti-inflammatory properties. These compounds not only improve blood flow but also reduce inflammation and promote tissue healing. Ongoing research is focused on developing recombinant forms of hirudin and other leech-derived molecules to produce safer and more effective anticoagulant drugs with fewer adverse effects[1-4].

Maggots

Sterile larvae of the green bottle fly (*Lucilia sericata*) are widely used in maggot debridement therapy, an effective biological treatment for chronic and non-healing wounds. Maggots selectively consume necrotic tissue while leaving healthy tissue intact, making them highly effective in wound cleaning. They secrete a variety of proteolytic enzymes, including collagenases and serine proteases, which digest dead tissue. In addition, they produce antimicrobial peptides such as lucifensin that inhibit the growth of pathogenic bacteria, including antibiotic-resistant strains. Maggot secretions also help reduce inflammation, stimulate the formation of new blood vessels, and promote tissue regeneration. Because of these properties, maggot therapy is widely used in the treatment of diabetic foot ulcers, pressure ulcers, venous leg ulcers, and burn wounds. Future studies aim to isolate individual antimicrobial compounds from maggot secretions for the development of new antibiotics and advanced wound-healing products[5-8].

Honeybees

Honeybees (*Apis mellifera*) contribute significantly to medicine through products such as honey, bee venom, propolis, and royal jelly. Honey possesses remarkable antimicrobial and wound-healing properties due to its high sugar concentration, low pH, hydrogen peroxide, flavonoids, and phenolic compounds. These components inhibit bacterial growth, reduce inflammation, and accelerate tissue repair, making honey an effective natural wound dressing. Bee venom contains several biologically active peptides, including melittin, apamin, adolapin, and phospholipase A_2. Melittin exhibits strong anti-inflammatory, antimicrobial, antiviral, and anticancer activities, while apamin has neuroprotective effects by acting on potassium channels. Bee venom therapy has been investigated for conditions such as rheumatoid arthritis, multiple sclerosis, Parkinson's disease, and chronic pain. Recent advances in nanotechnology have enabled researchers to develop targeted drug delivery systems using melittin for cancer treatment, thereby reducing toxicity to healthy tissues[9-12].

Earthworms

Earthworms have long been used in traditional medicine and have recently attracted attention because of their therapeutic enzymes and proteins. The most important bioactive constituent obtained from earthworms is lumbrokinase, a group of fibrinolytic enzymes capable of dissolving blood clots. Lumbrokinase has demonstrated significant potential in the prevention and treatment of thrombosis, ischemic stroke, myocardial infarction, and other cardiovascular diseases. Earthworms also produce antimicrobial peptides and glycoproteins that exhibit antibacterial and anti-inflammatory activities. Experimental studies have suggested that these compounds may contribute to tissue repair and immune regulation. Future pharmaceutical research is directed toward developing purified lumbrokinase formulations and investigating their potential as safe oral thrombolytic agents[13-16].

Horseshoe Crabs

Although horseshoe crabs are not directly used as therapeutic agents, they play an indispensable role in modern medicine through their unique blue blood. The blood contains amebocytes that produce the Limulus Amebocyte Lysate (LAL), which reacts rapidly in the presence of bacterial endotoxins. This property has made the LAL test the international standard for detecting endotoxin contamination in injectable drugs, vaccines, intravenous fluids, and medical devices. The sensitivity of the LAL test has significantly improved pharmaceutical safety by preventing contaminated products from reaching patients. However, concerns regarding the conservation of horseshoe crab populations have encouraged the development of recombinant Factor C technology, which provides an equally effective and more sustainable alternative to the traditional LAL assay[17-20].

Marine Sponges

Marine sponges represent one of the richest sources of biologically active natural products. Living in highly competitive marine environments, these organisms produce numerous secondary metabolites that protect them from predators, microorganisms, and environmental stress. Many of these compounds have shown potent pharmacological activities. Cytarabine, originally derived from marine sponge nucleosides, is widely used in the treatment of leukemia and lymphoma, while vidarabine has been used as an antiviral drug. Other sponge-derived compounds, such as halichondrin B and discodermolide, exhibit powerful anticancer properties by interfering with microtubule formation and cell division. Marine sponge metabolites have also demonstrated antibacterial, antifungal, anti-inflammatory, and immunomodulatory activities. Modern approaches such as marine biotechnology, genome mining, and microbial fermentation are expected to facilitate the sustainable production of sponge-derived pharmaceuticals[21-24].

Cone Snails

Cone snails (*Conus* species) are venomous marine molluscs that produce a complex mixture of neuroactive peptides known as conotoxins. These peptides exhibit exceptional specificity for ion channels, receptors, and neurotransmitter transporters within the nervous system. Among these compounds, ω-conotoxins have gained considerable medical importance because they block voltage-gated calcium channels involved in pain transmission. The synthetic form of one such peptide, ziconotide, has been approved for the management of severe chronic pain in patients who do not respond to conventional opioid therapy. Unlike opioids, ziconotide does not cause dependence or respiratory depression. Ongoing research is exploring the use of various conotoxins for treating epilepsy, Parkinson's disease, Alzheimer's disease, and other neurological disorders. Their high selectivity makes them promising candidates for the development of safer neurological drugs[25-28].

Silkworms

Silkworms (*Bombyx mori*) have contributed to medicine through the production of silk proteins, particularly fibroin and sericin. These proteins possess excellent biocompatibility, biodegradability, mechanical strength, and minimal immunogenicity. Silk has been used for decades as a surgical suture material because of its durability and compatibility with human tissues. More recently, fibroin- and sericin-based biomaterials have been employed in wound dressings, tissue engineering, artificial skin, bone regeneration, and controlled drug delivery systems. Silk scaffolds provide an ideal environment for cell attachment and tissue regeneration, making them valuable in regenerative medicine. Future research is focused on engineering silk-based biomaterials capable of delivering stem cells, growth factors, and therapeutic drugs directly to damaged tissues[29-32].

Table: A summary of invertebrates along with their active constituents and uses

Invertebrate	Major active constituents	Medicinal uses
Medicinal leech	Hirudin, Calin, Destabilase	Anticoagulation, reconstructive surgery
Maggots	Lucifensin, proteolytic enzymes	Wound debridement
Honeybee	Melittin, flavonoids, apamin	Wound healing, anti-inflammatory therapy
Earthworm	Lumbrokinase	Thrombosis, cardiovascular diseases
Horseshoe crab	Limulus Amebocyte Lysate (LAL), Factor C	Endotoxin detection
Marine sponge	Cytarabine, Vidarabine, Halichondrin B	Cancer, viral infections
Cone snail	Conotoxins	Chronic pain management
Silkworm	Fibroin, Sericin	Tissue engineering, wound healing

Challenges

Although invertebrate-derived therapeutics have shown remarkable clinical success, several challenges remain. These include sustainable harvesting of marine species, conservation of biodiversity, difficulties in large-scale production of bioactive compounds, variability in chemical composition, high manufacturing costs, potential toxicity, immunogenicity, and the need for extensive clinical trials to establish safety and efficacy. Advances in recombinant DNA technology, synthetic biology, and biotechnology are helping overcome many of these limitations.

Future Perspectives

The role of invertebrates in medicine is expected to expand significantly in the coming years due to advances in biotechnology, molecular biology, and pharmaceutical sciences. Emerging technologies such as genomics, proteomics, metabolomics, artificial intelligence-assisted drug discovery, and CRISPR-based genetic engineering are accelerating the identification of novel bioactive compounds from invertebrates. Marine biotechnology and microbial fermentation are providing sustainable methods for producing valuable therapeutic molecules without excessive harvesting of natural populations. Nanotechnology-based drug delivery systems are further enhancing the stability, targeting ability, and therapeutic efficiency of invertebrate-derived compounds. As the global burden of antimicrobial resistance, cancer, cardiovascular diseases, and neurological disorders continues to increase, invertebrate-derived natural products are expected to become an increasingly important source of innovative medicines. Continued interdisciplinary research and well-designed clinical trials will be essential for translating these promising biological molecules into safe, effective, and commercially available pharmaceutical products.

Conclusion

Invertebrates have become an indispensable source of bioactive compounds with significant pharmaceutical and biomedical applications. Medicinal leeches, maggots, honeybees, earthworms, horseshoe crabs, marine sponges, cone snails, and silkworms contribute to modern medicine through their unique therapeutic molecules and biological products. Their applications range from wound healing and anticoagulation to cancer therapy, pain management, tissue engineering, and diagnostic testing. Continued research, combined with advances in biotechnology and sustainable production methods, is expected to expand the clinical use of invertebrate-derived compounds and facilitate the development of safer, more effective treatments for a wide range of medical conditions.

References

1. Whitaker IS, Izadi D, Oliver DW, Monteath G, Butler PE. *Hirudo medicinalis*: ancient origins of, and trends in the use of medicinal leeches throughout history. Br J Oral Maxillofac Surg. 2004;42(2):133–137.
2. Hildebrandt JP, Lemke S. Small bite, large impact: saliva and salivary molecules in the medicinal leech *Hirudo medicinalis*. Naturwissenschaften. 2011;98(12):995–1008.
3. Sig AK, Guney M, Uskudar Guclu A, Ozmen E. Medicinal leech therapy—an overall perspective. Integr Med Res. 2017;6(4):337–343.
4. Lemke S, Vilcinskas A. European medicinal leeches—new roles in modern medicine. Biomedicines. 2020;8(5):99.
5. Sherman RA, Hall MJR, Thomas S. Medicinal maggots: an ancient remedy for some contemporary afflictions. Annu Rev Entomol. 2000; 45:55–81.
6. Sherman RA. Maggot therapy for treating diabetic foot ulcers unresponsive to conventional therapy. Diabetes Care. 2003;26(2):446–451.
7. Mumcuoglu KY. Clinical applications for maggots in wound care. Am J Clin Dermatol. 2001;2(4):219–227.
8. Nigam Y, Bexfield A, Thomas S, Ratcliffe NA. Maggot therapy: the science and implication for CAM. Evid Based Complement Alternat Med. 2006;3(2):223–227.
9. Molan PC. The evidence supporting the use of honey as a wound dressing. Int J Low Extrem Wounds. 2006;5(1):40–54.
10. Bogdanov S. Honey as a nutrient and functional food. Bee Product Science. 2012.
11. Oršolić N. Bee venom in cancer therapy. Cancer Metastasis Rev. 2012;31(1–2):173–194.
12. Pasupuleti VR, Sammugam L, Ramesh N, Gan SH. Honey, propolis and royal jelly: a comprehensive review of their biological actions and health benefits. Oxid Med Cell Longev. 2017.
13. Cooper EL, Balamurugan M. Unearthing a source of medicinal molecules: earthworms. Drug Discov Today. 2010;15(21–22):966–972.

14. Balamurugan M, Parthasarathi K, Cooper EL, Ranganathan LS. Anti-inflammatory and antimicrobial activities of earthworm extracts. Eur Rev Med Pharmacol Sci. 2007.
15. Cooper EL. Earthworms: sources of antimicrobial and anticancer molecules. Evid Based Complement Alternat Med. 2004.
16. Cho IH, et al. Lumbrokinase: a new fibrinolytic enzyme for the prevention of thrombosis. J Enzyme Inhib Med Chem. 2004.
17. Levin J, Bang FB. The role of endotoxin in the extracellular coagulation of *Limulus* blood. Bull Johns Hopkins Hosp. 1964.
18. Novitsky TJ. Biomedical applications of Limulus amebocyte lysate. Methods Mol Biol. 1994.
19. Maloney T, et al. The biomedical harvest of horseshoe crabs and conservation issues. Rev Fish Sci Aquac. 2018.
20. Dubczak J, et al. Recombinant Factor C assay for bacterial endotoxin detection. PDA J Pharm Sci Technol. 2020.
21. Mehbub MF, Lei J, Franco C, Zhang W. Marine sponge derived natural products between 2001 and 2010: trends and opportunities for discovery of bioactives. Mar Drugs. 2014.
22. Mayer AMS, et al. Marine pharmacology in 2014–2015: marine compounds with antibacterial, antidiabetic, antifungal, anti-inflammatory, antiparasitic, antiviral and anticancer activities. Mar Drugs. 2019.
23. Blunt JW, Copp BR, Munro MHG, Northcote PT, Prinsep MR. Marine natural products. Nat Prod Rep. (Annual review series).
24. Newman DJ, Cragg GM. Natural products as sources of new drugs. J Nat Prod. 2020.
25. Favreau P, Stöcklin R. Marine snail venoms: use and trends in receptor and channel neuropharmacology. Curr Opin Pharmacol. 2009;9(5):594–601.
26. Olivera BM. Conus peptides: biodiversity-based discovery and exogenomics. J Biol Chem. 2006.
27. Miljanich GP. Ziconotide: neuronal calcium channel blocker for severe chronic pain. Curr Med Chem. 2004.
28. Lewis RJ, Dutertre S, Vetter I, Christie MJ. Conus venom peptide pharmacology. Pharmacol Rev. 2012.
29. Singh KP, Jayasomu RS. *Bombyx mori*—A review of its potential as a medicinal insect. Pharm Biol. 2002;40(1):28–32.
30. Kundu B, Kurland NE, Bano S, et al. Silk proteins for biomedical applications. Prog Polym Sci. 2014.
31. Altman GH, Diaz F, Jakuba C, et al. Silk-based biomaterials. Biomaterials. 2003;24(3):401–416.
32. Vepari C, Kaplan DL. Silk as a biomaterial. Prog Polym Sci. 2007;32(8–9):991–1007.